icon
icon
icon
icon
🏷️$300 Off
🏷️$300 Off

News /

Articles /

Telix ADSs Commence Trading on Nasdaq: A New Era for Global Investors

Eli GrantWednesday, Nov 13, 2024 4:38 pm ET
4min read
Telix Pharmaceuticals Limited (TLX) has made a significant stride in its global expansion by listing its American Depositary Shares (ADSs) on the Nasdaq Global Select Market. This move, which commenced on November 14, 2024, is set to facilitate streamlined access to Telix shares for U.S. and global investors, while complementing the company's primary listing on the Australian Securities Exchange (ASX).

The Nasdaq listing of Telix's ADSs under the ticker symbol 'TLX' is an important milestone for the biopharmaceutical company, as it aligns with its strategic goals to broaden its global investor base and attract top talent. This move comes at a time when Telix's North American presence is expanding through both organic growth and acquisitions, with the majority of its employees now based in the U.S.

The Level II American Depositary Receipt (ADR) program established by Telix simplifies access to the company's ordinary shares on the Nasdaq Stock Market (Nasdaq). This program allows investors to purchase ADSs, which represent the Company’s ordinary shares, without the need for complex cross-border transactions or currency conversions. By establishing a Level II ADR program, Telix aims to facilitate significant interest from U.S. and global investors, as well as simplify access to the Company’s securities and equity-related incentives for U.S. domiciled employees.

W, SMR, CELH, BTM, MSTR...Turnover Rate, Trading Volume


The Nasdaq listing is expected to enhance Telix's visibility in the dynamic biopharmaceutical market, further supporting its growth trajectory and leadership position in radiopharmaceuticals. With the majority of Telix's employees now based in the U.S., the Nasdaq listing simplifies access to Telix's securities and equity-related incentives for U.S. domiciled employees, aligning with Telix's strategic goals to attract and retain the highest calibre of talent.

In conclusion, the Nasdaq listing of Telix's ADSs is a strategic move that complements the company's primary ASX listing and expands its global investor base. This move aligns with Telix's strategic goals to broaden its global investor base, attract U.S.-domiciled talent, and increase visibility in the dynamic biopharmaceutical market. Despite not issuing new shares, the Nasdaq listing enhances Telix's visibility and reputation, further supporting its growth trajectory and leadership position in radiopharmaceuticals.
Comments

Add a public comment...
Post
No Comment Yet
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
You Can Understand News Better with AI.
Whats the News impact on stock market?
Its impact is
fork
logo
AInvest
Aime Coplilot
Invest Smarter With AI Power.
Open App